Boehringer Ingelheim Signs $7B Oncology Deal with SBP Group

Boehringer Ingelheim has entered into a major oncology partnership with China’s Sino Biopharmaceutical Limited (SBP Group) to develop next-generation cancer treatments using antibody-drug conjugates (ADCs) and T-cell engager technologies.

Announced on November 4, 2026, the strategic agreement covers six early-stage biological drug development programmes and could bring SBP Group up to US$7 billion in milestone payments, in addition to upfront payments and royalties from future product sales.

Under the agreement, SBP Group will receive US$358 million in upfront and near-term payments. It will also be eligible for additional payments linked to the achievement of development, regulatory and commercial milestones, as well as tiered royalties on potential future sales.

The collaboration will focus on six preclinical programmes. Five of these are being developed by LaNova Medicines, a wholly owned subsidiary of SBP Group, while the remaining programme comes from another subsidiary, Beijing Tide Pharmaceutical.

The companies aim to combine SBP Group’s drug discovery platforms and early-stage development capabilities with Boehringer Ingelheim’s global research and development expertise. The partnership is expected to strengthen the development of new cancer treatments for patients with difficult-to-treat cancers.

Under the agreement, SBP Group will initially handle the early development of the programmes. Once agreed clinical milestones are achieved, Boehringer Ingelheim will have the option to take exclusive development, manufacturing and commercialisation rights.

For four of the programmes, these rights will cover markets outside mainland China, Hong Kong and Macau. For the remaining two programmes, Boehringer Ingelheim will have the option to obtain worldwide rights.

The collaboration will focus on two important areas of cancer drug development: antibody-drug conjugates and T-cell engagers.

ADCs are designed to deliver powerful cancer-killing drugs directly to cancer cells while limiting damage to healthy tissues. They combine an antibody that recognises specific targets on cancer cells with a drug designed to destroy them.

T-cell engagers work differently. They are designed to bring T cells, which are part of the body’s immune system, close to cancer cells so that they can recognise and attack them.

Both approaches are gaining attention in oncology research because they offer new ways to target cancer and potentially improve treatment outcomes.

Paola Casarosa, Member of the Board of Managing Directors and Head of the Innovation Unit at Boehringer Ingelheim, said the partnership would help expand the company’s ADC and T-cell engager portfolio. She also highlighted the importance of connecting innovation from China with Boehringer Ingelheim’s global research and development capabilities.

Theresa Tse, Chairwoman of SBP Group, described the agreement as an important milestone in the company’s international growth strategy. She said the partnership would further demonstrate the strength of its research platforms and help bring innovative cancer treatments to patients worldwide.

The agreement builds on an existing relationship between the two companies. Their first oncology collaboration was established in 2024, focusing on the development and commercialisation of Boehringer Ingelheim’s cancer medicines in mainland China.

The new agreement expands their relationship by allowing Boehringer Ingelheim to access early-stage drug development programmes from SBP Group for potential development in international markets.

The partnership also supports Boehringer Ingelheim’s growing presence in China’s pharmaceutical innovation sector. The company recently opened a China Research and Development Centre in Shanghai to strengthen its early clinical development activities and connect local scientific discoveries with its global research network.

With six preclinical programmes now included in the collaboration, the agreement gives Boehringer Ingelheim an opportunity to expand its oncology pipeline while supporting SBP Group’s international development plans.

The next major step will be advancing these early-stage programmes through development and clinical testing to determine their potential as future cancer treatments.